Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger

Kyle LaHucik

Senior Reporter

The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital’s shell company Concentra Biosciences, clearing up any doubt about its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same

Sofinnova Partners raises €1.2B to back another 50 to 60 life sciences startups

Bourla says Pfizer could transfer production to US to sidestep Trump's tariffs

23andMe rejects CEO's second take-private offer

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Ace­lyrin re­jects buy­out of­fer from Tang’s Con­cen­tra, sticks to Alu­mis merg­er

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger